You are here: Industry Insights > pneumonia

News List

RedHill Biopharma Announces Positive Recommendation from COVID-19 Study americanpharmaceuticalreview
August 31, 2020
RedHill Biopharma announced its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia, has successfully passed the first scheduled independent Safety Monitoring Committee (SMC) review.
Tradipitant may accelerate recovery from COVID-19 pneumonia, finds interim analysis europeanpharmaceuticalreview
August 20, 2020
A preliminary analysis of data from the first COVID-19 pneumonia patients enrolled in the ODYSSEY trial revealed that tradipitant may expedite clinical improvement.
Blade Therapeutics updates enrolment progress for Covid-19 pneumonia study of BLD-2660 pharmaceutical-business-review
August 18, 2020
Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients.
BioAegis Therapeutics Initiates Trial of Its Inflammation Regulator for COVID-19 Treatment americanpharmaceuticalreview
August 07, 2020
BioAegis Therapeutics enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia.
Nabriva Receives EC Approval for XENLETA for Community-Acquired Pneumonia americanpharmaceuticalreview
August 05, 2020
Nabriva Therapeutics announced the European Commission (EC) has issued a legally binding decision for approval of the marketing authorization application for XENLETA™ (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults ...
Enzychem Files IND for Phase 2 Study of EC-18 in Preventing ARDS Due to COVID-19 Pneumonia americanpharmaceuticalreview
July 22, 2020
Enzychem Lifesciences has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of EC-18 as a preventative therapeutic against Acute Respiratory Disease Syndrome (ARDS) due to ...
BioAegis Therapeutics receives approval to proceed with phase 2 trial of its gelsolin Covid-19 treatment pharmaceutical-business-review
July 21, 2020
BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in ...
Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19 worldpharmanews
June 17, 2020
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia.
PolyU collaborates with Macau, S.A.R., China University of Science and Technology to advance diagnosis of COVID-19 pneumonia prnewswire
June 16, 2020
COVID-19 is taking its toll on the world, affecting more than 200 countries and regions. In the face of a surge in cases, rapid diagnosis and identification of high-risk patients for early intervention is crucial for controlling the pandemic.
FDA Accepts sNDA with Priority Review for FETROJA americanpharmaceuticalreview
June 11, 2020
Shionogi announced the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for FETROJA® (cefiderocol) and granted Priority Review designation ...

Previous page 1 2 3 4 5 Next page